At present, in addition to the IND approved E10H (a cell therapy product), Doublle's independent research and development projects also include CAR-NK, CAR-T ,all of which have entered the stage from pre-clinical into the process of clinical research..

   Chimeric Antigen Receptor T cells/NK cells refer to the positioning and navigation device CAR installed on T cells/NK cells through genetic engineering technology. CAR includes extracellular recognition domains (such as scFv) to recognize tumor-specific antigens; a trans-membrane domain, and an intracellular signaling domain (CD3ζ chain). Chimeric antigen receptors can significantly improve the therapeutic specificity of T cells/NK cells. In recent years, there have been many preclinical studies on targeted CAR-NK cell therapy, which have shown a good efficacy in tumor treatment.